Testing effectiveness (Phase 2)Not Yet RecruitingNCT05904626
What this trial is testing
Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA
Who this might be right for
Intestinal Malabsorption
Elgan Pharma Ltd. 60